Ventripoint Diagnostics Ltd (CVE:VPT) (OTCQB:VPTDF) said Tuesday that it staged a successful hands-on demonstration of its next-generation VMS+3.0 system at the American College of Cardiology’s 68th Annual Scientific Session & Expo in New Orleans over the weekend (March 16-March 18).
Not yet available for sale, the VMS+3.0 system is Ventripoint’s latest version of its machine, which revolutionizes the way doctors treat heart patients as it can give accurate and rapid volumetric information about all four chambers of the heart.
READ: VentriPoint Diagnostics' heart monitoring tech further boosted by agreement with Canadian government
It is the only technology in the world that can perform such an analysis of all four chambers using data from a conventional 2D (two dimensional) eco-cardiogram (in other words an ultrasound test).
Ventripoint's most up-to-date 3.0 system uses sensor technology, which allows for patients to move during the imaging portion of the examination, and it is compact and portable enough that it can be set up within minutes.
The Toronto company seized the opportunity to showcase the latest advances in its technology at the ACC’s Annual Scientific Session & Expo, which was attended by nearly 20,000 cardiologists.
The VMS+3.0 system is for investigational use only.
Ventripoint has developed a suite of applications to monitor heart disease. Its VMS+ system is the first AI tool for measuring the function of the entire heart using ultrasound.
Ventripoint shares closed at C$0.175 in Canadian trade on Monday.
Contact Ellen Kelleher at [email protected]